HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MCRB
Seres Therapeutics, Inc.
There isn't enough reported data to score MCRB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MCRB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MCRB's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MCRB PE Valuation
MCRB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MCRB Forward outlook
There aren't enough analyst estimates for MCRB to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MCRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.02 | -910% |
| Q2 2026 | -$2.45 | -122% |
| Q1 2026 | -$5.19 | -157% |
| Q4 2025 | $0.64 | +$0.64 |
| Q3 2025 | $0.62 | +$5.02 |
| Q2 2025 | $11.28 | +$34.68 |
| Q1 2025 | $9.15 | +$20.95 |
| Q4 2024 | $0.00 | +$17.71 |
MCRB has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MCRB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MCRB on profitability, with a higher operating margin.
MCRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $593K | +69% |
| Q4 2023 | $64K | -93% |
| Q3 2023 | $310K | -91% |
| Q2 2023 | $126.5M | +10301% |
| Q4 2022 | $975K | -86% |
| Q3 2022 | $3.4M | -97% |
| Q2 2022 | $1.2M | -77% |
| Q1 2022 | $1.5M | -74% |
MCRB's revenue is recovering but still below its 2021 peak: $593,000 last quarter, up 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2724% | +3680 points |
| Q2 2026 | -2890% | N/A |
| Q1 2026 | -5840% | N/A |
| Q4 2025 | -4424% | N/A |
| Q3 2025 | -6404% | N/A |
| Q4 2023 | -61759% | -54754 points |
| Q3 2023 | -15295% | -13578 points |
| Q2 2023 | 39% | +5247 points |
MCRB's operating margin was −2724% last quarter, up 3680 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MCRB on cash generation, producing positive trailing cash flow while its opponent burns cash.
MCRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -577% |
| Q2 2026 | -$22.4M | -$8.9M |
| Q1 2026 | -$16.4M | -161% |
| Q4 2025 | -$14.7M | +$24.2M |
| Q3 2025 | $2.2M | +$37M |
| Q2 2025 | -$13.5M | +$26.4M |
| Q1 2025 | $26.9M | +$62.2M |
| Q4 2024 | -$39M | +$9.4M |
MCRB has burned cash in almost every quarter: −$64M over the past year, against −$23M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MCRB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MCRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +235K shares |
| 1 year | +14% | +1.2M shares |
| 3 years | +56% | +3.6M shares |
| 5 years | +110% | +5.2M shares |
| Available history | +182% | +6.4M shares |
MCRB has 10M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MCRB Net Leverage
MCRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MCRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.9 | Oversold |
MCRB's weekly RSI is 25 (oversold) and its Stochastic is 4 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MCRB PE vs Healthcare Sector
| Metric | MCRB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MCRB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MCRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.36 | 40% below |
| 20 week MA | $4.08 | 65% below |
| 50 week MA | $7.91 | 82% below |
| 100 week MA | $11.2 | 87% below |
| 200 week MA | $29.8 | 95% below |
MCRB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MCRB on returns for 2026, with the stronger performance.
MCRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.0 | $485.6 | +507% |
| 2021 | $485.6 | $183.4 | -62% |
| 2022 | $183.4 | $104.8 | -43% |
| 2023 | $104.8 | $28.0 | -73% |
| 2024 | $28.0 | $17.7 | -37% |
| 2025 | $17.7 | $14.7 | -17% |
| 2026 YTD | $14.7 | $1.41 | -90% |
MCRB has finished five years in a row lower, and it's down 90% so far in 2026.